Case Study: Pre-Clinical Landscape Assessment
A global pharmaceutical company was developing a new product for the treatment of Parkinson’s disease; the product had a novel mechanism of action and was in early phase of clinical development
Latest team promotions at Windrose
Windrose Consulting Group are pleased to announce the October promotions within our team.
Windrose Consulting Group acquires Parioforma as part of its global growth strategy to further enhance its capabilities in non-traditional markets.
Windrose Consulting Group acquires Parioforma as part of its global growth strategy to further enhance its capabilities in non-traditional markets.
Case Study: Framework and Policy Development
A global pharmaceutical company’s R&D portfolio included several combination products across multiple different disease states.
Case Study: Global Pricing & Market Access Strategy for a Rare Disease Gene Therapy
A biopharmaceutical company was developing the first gene therapy for a rare disease. It was expected to be a one-time therapy that would replace the current chronic standard of care.
Case Study: Global Pricing Strategy for a New Vaccine
A global pharmaceutical company was planning to launch a next generation vaccine into a competitive market with the aim of replacing the current standard of care, which was a vaccine that they also owned.
Case Study: Indication expansion assessment and evidence requirements for a novel agent in alpha-thalassemia
A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines.
Windrose Consulting Group’s Response to Medicaid’s Proposed Changes to Best Price Calculations
In recent years, there has been a growing interest between pharmaceutical companies and payers to implement Value Based Agreements (VBAs) based on clinical outcomes. VBAs are typically applied when access is not attained through “standard” value communication and negotiation, driven by uncertainties around the clinical evidence and / or financial impact of the drug in question. As more and more curative and transformative therapies such as gene therapies enter the market, payers are looking for innovative ways to pay for these next-generation medicines, which are often accompanied with an astronomical price tag.
Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialization strategy
Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialization strategy
Matt Storer joins the Windrose leadership team.
Windrose Consulting Group is pleased to announce the addition of Matt Storer to the leadership team. Matt joins as a Partner based in the London office, and will be leading the European Consulting Operations.

